<DOC>
	<DOCNO>NCT00463567</DOCNO>
	<brief_summary>Stage 1 study design provide data risk-benefit 4 dose regimen indacaterol ( 75 , 150 , 300 &amp; 600 µg o.d . ) order select two dos carry forward study Stage 2 . Study Stage 2 provide pivotal confirmation efficacy , safety , tolerability select indacaterol dose patient COPD</brief_summary>
	<brief_title>26 Week Efficacy , Safety Tolerability Study Indacaterol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female adult age ≥ 40 year , sign Informed Consent Form prior initiation studyrelated procedure Cooperative outpatient diagnosis COPD ( moderate severe classify Global Initiative Chronic Obstructive Pulmonary Disease ( GOLD ) Guidelines , 2005 ) : Smoking history least 20 pack year Postbronchodilator FEV1 &lt; 80 % ≥ 30 % predict normal value . Postbronchodilator FEV1/FVC &lt; 70 % ( Post refers within 30 min inhalation 400 µg salbutamol ) Pregnant lactate female Patients hospitalize COPD exacerbation 6 week prior Visit 1 runin period Patients require long term oxygen therapy ( &gt; 15 h day ) Patients respiratory tract infection 6 week prior V1 ( criterion ) Patients concomitant pulmonary disease , pulmonary tuberculosis , clinically significant bronchiectasis Patients history asthma ( criterion ) Patients Type I uncontrolled Type II diabetes Patients contraindication tiotropium Patients clinically relevant laboratory abnormality clinically significant abnormality Any patient active cancer history cancer le 5 year disease free survival time Patients history long QT syndrome whose QTc interval prolong Patients hypersensitivity study drug drug similar chemical structure Patients treatment investigational drug ( criterion ) Patients live attenuate vaccination within 30 day prior visit 1 , runin period Patients know history non compliance medication Patients unable satisfactorily use dry powder inhaler device perform spirometry measurements Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>long act beta-2 agonist</keyword>
</DOC>